How to Pay Less for Insulin in 2026: State Caps, Medicare's $35 Limit, and Drugmaker Programs
Average insulin costs have fallen since 2018, but what you pay still depends on who regulates your plan. A U.S. guide to state copay caps, the Medicare cap, Lilly, Novo Nordisk, and Sanofi programs, lower-cost insulins, and health centers, with a short global note.
Key points
- Average out-of-pocket insulin costs for a one-month supply fell from $39.13 in 2018 to $18.26 in 2025 for commercially insured people and from $42.79 to $12.04 in Medicare, in December 2025 dollars, according to a July 2026 ASPE issue brief
- The American Diabetes Association lists 29 states plus D.C. with insulin copay caps for state-regulated commercial plans; North Dakota's 2025 cap is $25 a month
- State caps generally do not reach self-funded employer plans governed by ERISA, which covered 67% of workers with job-based coverage in KFF's 2025 survey (80% at firms with 200 or more workers)
- Medicare limits cost sharing to $35 for a one-month supply of each covered insulin product under Part D and Part B, with no deductible and a $105 limit on a three-month supply
- Lilly and Novo Nordisk sell their insulins for $35 a month to commercially insured and uninsured people but generally exclude government plans; Sanofi says its $35 program has been open to all U.S. patients, including Medicare enrollees, since January 1, 2026
- Lower-cost options include biosimilar and unbranded insulins, California's CalRx glargine at a suggested $55 for five pens, and human insulin at $25 a vial at Walmart; switching insulins requires clinician guidance
- Executive Order 14273 (April 2025) directed HHS to require federally funded health centers to offer insulin at or below their 340B price plus a minimal fee to eligible low-income patients
- Utah is collecting patient testimony for its November 2023 lawsuit against insulin makers and PBMs, and Congress is considering a national insulin cap
The short version
Insulin is a peptide hormone, a small protein the pancreas makes to move sugar out of the blood and into cells. People with type 1 diabetes make little or none of it, and many people with type 2 diabetes need it as well. About a fifth of the estimated 40 million Americans with diabetes depend on insulin, according to a November 13, 2026 report from NPR and KFF Health News.
In late 2026, what you pay depends less on the insulin than on how you buy it. Medicare caps each covered insulin at $35 a month. Twenty-nine states plus D.C. cap copays in the plans they regulate, but most large employers' plans fall outside those laws. Lilly, Novo Nordisk, and Sanofi each sell their insulins for $35 a month through savings programs with different rules. Biosimilar, unbranded, and human insulins cost less still. Changing insulins is a medical decision: talk to your prescriber first, and do not stretch or skip doses to save money.
How far costs have fallen since 2018
A July 2026 issue brief from the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) used claims data, adjusted to December 2025 dollars, to track the average out-of-pocket cost of a one-month insulin supply. For commercially insured people it fell from $39.13 in 2018 to $18.26 in 2025. In Medicare it fell from $42.79 to $12.04. For the roughly 2% of prescriptions paid in cash or through assistance programs, it fell from $212.81 to $70.93. NPR and KFF Health News, citing federal data, put average yearly costs for privately insured people at $470 in 2018 and $220 in 2025.
Part of the drop came from list prices. The list price is the price a manufacturer sets before discounts and rebates, also called the wholesale acquisition cost (WAC). In March 2023, Lilly announced 70% cuts for Humalog and Humulin and a $25-per-vial list price for its unbranded insulin lispro. Novo Nordisk announced cuts of up to 75% for NovoLog and 65% for Levemir and Novolin, and Sanofi a 78% cut for Lantus. ASPE says most cuts took effect in late 2023 or January 2024, and it cites research pointing to the end of a cap on Medicaid rebates on January 1, 2024 as one reason the companies cut.
Step 1: find out whether a state cap covers you
The American Diabetes Association lists 29 states plus D.C. with insulin copay caps for state-regulated commercial plans. North Dakota, whose 2025 law NPR profiled, caps insulin at $25 a month, as do Texas, Massachusetts, and New Mexico. Utah's cap is $30. California's $35 cap covers large-group plans now and small-group plans starting January 1, 2027. New York requires $0 cost sharing.
The gap is ERISA, the 1974 federal law that governs most job-based benefit plans. Many employers are self-funded (also called self-insured): the employer pays workers' medical claims from its own money, often hiring an insurer only to run the plan. KFF explains that ERISA keeps most state insurance laws, including benefit mandates, from applying to self-funded plans. In KFF's 2025 Employer Health Benefits Survey, 67% of workers with job-based coverage were in self-funded plans, including 80% at firms with 200 or more workers.
How to check:
- Ask your HR or benefits office: is our health plan fully insured or self-funded?
- If it is fully insured and your state has a cap, the cap applies. If you are charged more, call the insurer, then your state insurance department.
- If it is self-funded, your employer can still choose to limit insulin costs. Ask whether it covers insulin before the deductible; since 2019, IRS rules let HSA-eligible high-deductible plans do that, according to ASPE.
- Plans you buy yourself, including marketplace plans, are state-regulated.
Medicare: $35 per insulin, per month
The Inflation Reduction Act of 2022 capped insulin costs for Part D, Medicare's drug benefit sold through private plans, starting January 1, 2023, and for Part B insulin used in a traditional pump starting July 1, 2023. According to CMS and Medicare.gov:
- You pay no more than $35 for a one-month supply of each covered insulin, with no deductible, and no more than $105 for a three-month supply.
- The cap applies at preferred and non-preferred pharmacies and to people with partial Extra Help.
- "Covered" means the insulin is on your plan's drug list (formulary). If yours is not listed, ask your prescriber about the covered option or an exception.
- Pumps and other equipment are not capped, and neither are non-insulin diabetes drugs such as Ozempic and Mounjaro. For weight-loss GLP-1 coverage, see our Medicare GLP-1 Bridge guide.
ASPE notes that from 2026 the Part D cap is the lesser of $35 or 25% of the plan's negotiated price (or of a Medicare-negotiated price), so some enrollees pay less. Medicare Plan Finder shows insulin costs by plan during open enrollment, which runs through December 7. Most maker programs below exclude Medicare enrollees; Sanofi says its program does not.
Maker programs: $35 a month, different rules
These are company policies, not laws, and each company says its terms can change.
Lilly Insulin Value Program. Lilly says all its insulins, including Humalog, Humulin, Lyumjev, Basaglar, Rezvoglar, and unbranded Insulin Lispro, cost $35 a month for people with commercial insurance or no insurance. The uninsured card requires you to be 18 or older, allows 14 fills per insulin per year, and expires December 31, 2026. People in Medicare, Medicaid, VA, TRICARE, or a state drug assistance program are excluded. Phone: 1-800-545-5979.
Novo Nordisk MyInsulinRx. Novo's terms offer a monthly supply of any combination of its insulins for $35, up to 3 vials or 2 packs of pens, including NovoLog, Fiasp, Tresiba, and Novolin. Uninsured and commercially insured patients qualify. New applicants in government programs cannot join, though Medicare Part D patients enrolled since 2020 can stay. Everyone re-enrolls yearly. The same terms price the once-weekly insulin Awiqli at $55 a month (see our weekly insulin pricing guide). Phone: 1-888-910-0632.
Sanofi Insulins Valyou. Sanofi says that since January 1, 2026, any U.S. patient with a valid prescription, including people with commercial insurance or Medicare, can get a 30-day supply of any combination of its insulins (Lantus, Toujeo, Admelog, Apidra, Merilog, and Soliqua 100/33) for $35. Its announcement does not mention Medicaid. ASPE notes that to get one $35 price across several Sanofi products, you fill them together. Phone: 1-888-847-4877.
TrumpRx.gov, the federal price site launched in February 2026, also lists insulin. ASPE found Lilly's insulin lispro there at $25 for one 10 mL vial and $35 for 2 to 4 vials. Our TrumpRx buyer's guide explains the site.
Lower-cost insulins to ask about
A biosimilar is a close copy of a biologic medicine that the FDA has found has no clinically meaningful differences from the original. An interchangeable biosimilar can be swapped in by the pharmacist without a new prescription where state law allows.
- Glargine (long-acting): Semglee (insulin glargine-yfgn) became the first interchangeable biosimilar of any drug in 2021, according to ASPE. Lilly's Rezvoglar is another option.
- Aspart (mealtime): The FDA approved Merilog (insulin aspart-szjj), the first rapid-acting insulin biosimilar, on February 14, 2025. ASPE reports Kirsty (insulin aspart-xjhz) followed as an interchangeable in July 2025.
- CalRx glargine: The nonprofit Civica makes glargine pens interchangeable with Lantus, sold under California's CalRx brand since January 2026 at a suggested maximum of $55 for five 3 mL pens. Civica said it would also supply pharmacies nationwide. KFF Health News reported in August 2026 that California had distributed more than 120,000 packs but that the pens were slow to reach pharmacies. Ask your pharmacy to order them.
- Human insulin: Regular (R), NPH (N), and premixed 70/30 human insulins are older products that can be sold without a prescription, though pharmacies keep them behind the counter. NovoCare says human insulin costs $25 a vial at Walmart under the ReliOn name.
A safety warning on human insulin. ASPE calls human insulins effective but imperfect substitutes for modern insulins, with more rigid meal timing and a higher risk of low blood sugar. The World Health Organization's November 2026 guideline calls human insulin an appropriate and effective option, but that does not make switching on your own safe. Doses and timing often change. Switch only with your prescriber, and ask how often to check your blood sugar while you adjust.
If you are uninsured or have a low income
Medicaid generally charges only nominal copays for drugs, ASPE says.
Community health centers. Federally qualified health centers (FQHCs) must serve patients regardless of ability to pay and offer sliding-fee discounts based on income. Many buy drugs through 340B, a federal program that lets safety-net clinics buy outpatient drugs at steep discounts. Executive Order 14273, signed April 15, 2025, directed HHS to require health centers to offer insulin at or below their 340B price plus a minimal fee to low-income patients who are uninsured, face high cost sharing, or have a high unmet deductible. You need to become a patient, and ASPE notes that what you pay depends on the center's pharmacy setup. Find one at findahealthcenter.hrsa.gov.
Pharmacy discounts. ASPE describes Costco's member program pricing some insulins near $35 and Amazon Pharmacy applying eligible maker coupons automatically.
Urgent need. Sanofi also runs a Temporary Access Program that, according to Managed Healthcare Executive, can provide a free one-time 30-day supply to qualifying low- and middle-income patients.
Options at a glance
- Medicare (Part D, or Part B pump insulin): $35 or less per covered insulin per month.
- State copay cap ($0 to $100): fully insured, state-regulated plans in 29 states plus D.C.; not most self-funded employer plans.
- Lilly ($35): commercially insured or uninsured; no government plans.
- Novo Nordisk ($35): commercially insured or uninsured; Medicare only if enrolled since 2020.
- Sanofi ($35): any U.S. patient with a prescription, Sanofi says, including Medicare.
- CalRx glargine ($55 for five pens): anyone with a prescription, with or without insurance, where stocked.
- Human insulin ($25 a vial at Walmart): anyone, after talking with a clinician.
- Community health centers (340B price plus a small fee): eligible low-income patients.
- Medicaid (nominal copays): people who qualify by income and state rules.
If you are about to run out
High prices pushed many people to ration insulin, "with sometimes deadly consequences," NPR and KFF Health News reported. Nina Kritzberger, a 17-year-old in North Dakota with type 1 diabetes, told NPR a missed dose could land her in the hospital.
If you cannot afford your next fill, ask your pharmacy for the price under each maker's program and any discount program, and call your prescriber about a cheaper covered insulin or a sample. If you have type 1 diabetes and are out of insulin, go to urgent care or an emergency room rather than going without.
Utah's lawsuit and a possible national cap
In November 2023, the Utah Attorney General's Office and the Utah Division of Consumer Protection sued insulin makers, including Eli Lilly and Novo Nordisk, and pharmacy benefit managers (PBMs), the companies that run drug benefits for insurers and employers and negotiate rebates with drugmakers. The complaint alleges the makers raised list prices to pay larger rebates to PBMs, and that PBMs favored high-rebate, high-cost drugs. The companies deny the claims, Utah News Dispatch reported on November 16, 2026. The Division now invites past and present Utah patients who used diabetes medication in the last 10 years to describe their experience on its website. Submissions count as formal consumer complaints and may be subject to legal discovery and public records requests.
NPR reported that Congress is considering a national insulin cap, with North Dakota Republican Sen. Kevin Cramer among its bipartisan co-sponsors. When the Medicare cap passed in 2022, Republican opposition sank a proposal to extend it to private insurance.
Outside the United States
On November 14, 2026, the World Health Organization published its first guidelines on type 1 diabetes in adults. WHO recommends multiple daily insulin injections with doses adjusted to blood sugar, calls human insulin an appropriate and effective option, and says many people with type 1 diabetes lack access to affordable, high-quality insulin.
In Europe, the European Medicines Agency's drug committee (CHMP) backed two insulin aspart biosimilars, Garzulys and Donrafylix, for people with diabetes aged 1 and older at its November 9 to 12 meeting. Both await a European Commission decision.
Limitations
- Manufacturer program terms change; Lilly's uninsured card is dated to expire December 31, 2026, and Novo requires yearly re-enrollment. Check terms before relying on them
- The ASPE figures are averages from claims data. People in high-deductible plans, or plans where they pay a percentage of the price (coinsurance), can still pay far more
- State cap amounts come from the American Diabetes Association's list; the page does not show a last-updated date, and some caps cover supplies or apply to collective totals rather than per product
- CalRx availability varies by pharmacy; KFF Health News reported a slow rollout in August 2026, and we could not confirm current stock outside California
- The Walmart human insulin price comes from Novo Nordisk's NovoCare site; we did not confirm in-store prices
- This guide covers costs, not treatment. It does not recommend any insulin or dose, and changing insulins needs a prescriber's guidance
Citations
- 1. Fed up with the healthcare industry, this red state capped insulin prices for patientsnews NPR / KFF Health News 2026
- 2. The Changing Insulin Affordability Landscape: Lower Out-of-Pocket Costs and Expanded Access Pathwaysregulatory HHS Office of the Assistant Secretary for Planning and Evaluation 2026
- 3. State Insulin Copay Capspatient-education American Diabetes Association 2026
- 4. Employer Health Benefits Survey 2025 Annual Survey: Summary of Findingsindustry-analysis KFF 2025
- 5. Health Policy 101: The Regulation of Private Health Insuranceindustry-analysis KFF 2025
- 6.
- 7. Insulin coverageregulatory Medicare.gov 2026
- 8. Lilly Insulin Value Programindustry Eli Lilly and Company 2026
- 9. MyInsulinRx Program Terms & Conditionsindustry Novo Nordisk (NovoCare) 2026
- 10. Find programs to receive low-cost human insulinindustry Novo Nordisk (NovoCare) 2026
- 11. Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the USpress-release Sanofi (via BioSpace) 2025
- 12. Sanofi to Offer All Sanofi Insulin for $35 a Month, Regardless of Income, Insurance Typenews Managed Healthcare Executive 2025
- 13.
- 14. Civica To Launch Long-Acting Insulin Glargine in the US in January 2026press-release Civica 2025
- 15. CalRx: Making prescription drugs more affordable for Californiansregulatory State of California 2026
- 16. Newsom Promotes Affordable Insulin, but California's Generic Label Off to a Slow Startnews KFF Health News 2026
- 17. Lowering Drug Prices by Once Again Putting Americans First (Executive Order 14273)regulatory Federal Register 2025
- 18. Utah is seeking diabetes patients' testimony to include in insulin price lawsuitnews Utah News Dispatch (via St. George News) 2026
- 19. Insulin pricing lawsuit: share your experienceregulatory Utah Division of Consumer Protection 2026
- 20. WHO issues first guidelines on type 1 diabetes for adultsregulatory World Health Organization 2026
- 21. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026regulatory European Medicines Agency 2026
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.